- Home
- CAPR vs OPFI Comparison
CAPR vs OPFI Comparison
Compare CAPR & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- OPFI
- Stock Information
- Founded
- CAPR 2005
- OPFI 2009
- Country
- CAPR United States
- OPFI United States
- Employees
- CAPR N/A
- OPFI N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- OPFI Finance: Consumer Services
- Sector
- CAPR Health Care
- OPFI Finance
- Exchange
- CAPR Nasdaq
- OPFI Nasdaq
- Market Cap
- CAPR 324.6M
- OPFI 300.3M
- IPO Year
- CAPR N/A
- OPFI N/A
- Fundamental
- Price
- CAPR $6.28
- OPFI $10.17
- Analyst Decision
- CAPR Strong Buy
- OPFI Buy
- Analyst Count
- CAPR 8
- OPFI 2
- Target Price
- CAPR $24.75
- OPFI $11.75
- AVG Volume (30 Days)
- CAPR 1.4M
- OPFI 1.3M
- Earning Date
- CAPR 08-11-2025
- OPFI 08-06-2025
- Dividend Yield
- CAPR N/A
- OPFI 9.79%
- EPS Growth
- CAPR N/A
- OPFI N/A
- EPS
- CAPR N/A
- OPFI N/A
- Revenue
- CAPR $13,392,150.00
- OPFI $320,831,000.00
- Revenue This Year
- CAPR N/A
- OPFI $116.69
- Revenue Next Year
- CAPR $6,061.53
- OPFI $9.90
- P/E Ratio
- CAPR N/A
- OPFI N/A
- Revenue Growth
- CAPR N/A
- OPFI 31.26
- 52 Week Low
- CAPR $3.98
- OPFI $3.93
- 52 Week High
- CAPR $23.40
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- OPFI 46.36
- Support Level
- CAPR $6.17
- OPFI $10.11
- Resistance Level
- CAPR $7.30
- OPFI $10.76
- Average True Range (ATR)
- CAPR 0.43
- OPFI 0.47
- MACD
- CAPR -0.11
- OPFI 0.08
- Stochastic Oscillator
- CAPR 4.53
- OPFI 51.49
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.